Loeki Aldenhoven
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Loeki Aldenhoven has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Alfred Janssen
Department of Surgery, Zuyderland Medical Center, Sittard-Geleen, The Netherlands
7 shared publicationsGeerard L. Beets
Department of Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands
6 shared publicationsJames van Bastelaar
Department of Surgery, Zuyderland Medical Center, Sittard-Geleen, The Netherlands
5 shared publicationsYvonne L. J. Vissers
Department of Surgery, Zuyderland Medical Center, Sittard-Geleen, The Netherlands
4 shared publications- James van Bastelaar
Department of Surgery, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands
3 shared publications Merel A. Spiekerman van Weezelenburg
Department of Surgery, Zuyderland Medical Center, Sittard-Geleen, The Netherlands
3 shared publications
Latest Publications
- Open Access
- 23 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Wide local excision margins in melanoma: a systematic review and network meta-analysis
Wide local excision (WLE) is essential in melanoma treatment to achieve clear margins. However, consensus on optimal excision margins to prevent local recurrence (LR) and increase melanoma-specific survival (MSS) is lacking. The aim of this study was to investigate the effect of surgical margins on LR and 5-year MSS in the treatment of patients with stage II melanoma (pT2b-pT4b, AJCC 8th edition). A literature search was performed in PubMed, EMBASE and Cochrane Library in October 2023. The network meta-analysis (NMA) was performed on LR and MSS, implementing a random effects model. A meta-regression analysis was performed to explore the association between margins and treatment effect. Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines were used. A total of 12 articles with 3988 patients were included. Margins of 1 cm compared to margins of 4 cm resulted in a higher OR for LR (OR 2.61; 95%CI [1.13–6.02]). MSS showed no statistically significant differences between 1 and 2 cm group (OR 1.22; 95%CI [0.86–1.74]). Comparable results for MSS were found comparing 1 cm versus 4 cm (OR 1.36; 95%CI [0.86–2.13]). The meta-regression showed a significant negative association between WLE margins and LR: OR = 0.45 per additional cm (95%CI [0.23–0.90], p = 0.023). Although 1 cm margins may not yet be established as standard care, the NMA offers an attractive alternative to summarize present findings and complement ongoing RCTs. Based on these results, a smaller margin tends to increase LR, but does not impact the MSS. This emphasizes the importance of the final results in the MelMarT-II study.
- 23 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessWide local excision margins in melanoma: a systematic review and network meta-analysis
Wide local excision (WLE) is essential in melanoma treatment to achieve clear margins. However, consensus on optimal excision margins to prevent local recurrence (LR) and increase melanoma-specific survival (MSS) is lacking. The aim of this study was to investigate the effect of surgical margins on LR and 5-year MSS in the treatment of patients with stage II melanoma (pT2b-pT4b, AJCC 8th edition). A literature search was performed in PubMed, EMBASE and Cochrane Library in October 2023. The network meta-analysis (NMA) was performed on LR and MSS, implementing a random effects model. A meta-regression analysis was performed to explore the association between margins and treatment effect. Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines were used. A total of 12 articles with 3988 patients were included. Margins of 1 cm compared to margins of 4 cm resulted in a higher OR for LR (OR 2.61; 95%CI [1.13–6.02]). MSS showed no statistically significant differences between 1 and 2 cm group (OR 1.22; 95%CI [0.86–1.74]). Comparable results for MSS were found comparing 1 cm versus 4 cm (OR 1.36; 95%CI [0.86–2.13]). The meta-regression showed a significant negative association between WLE margins and LR: OR = 0.45 per additional cm (95%CI [0.23–0.90], p = 0.023). Although 1 cm margins may not yet be established as standard care, the NMA offers an attractive alternative to summarize present findings and complement ongoing RCTs. Based on these results, a smaller margin tends to increase LR, but does not impact the MSS. This emphasizes the importance of the final results in the MelMarT-II study.
- Open Access
- 28 November 2025
- Published by S. Karger AG in European Surgical Research
- Vol. 67 (1) , 30-37
Exploring an Alternative Preoperative Sentinel Lymph Node Mapping Method Using a Magnetic Tracer and Magnetic Resonance Imaging for Melanoma Patients: SCARLETT Study Protocol
Introduction: Sentinel lymph node biopsy (SLNB) plays a critical role in the clinical management of malignant melanoma. The current standard of care involves the preoperative injection of a Technetium-labeled (99mTc) colloidal nanomaterial to facilitate lymphatic mapping. During surgery, patent blue (PB) is administered to enhance visualization of the lymphatic pathways. However, this dual-tracer approach presents notable drawbacks, including patient exposure to ionizing radiation and logistical challenges stemming from the short half-life of (99mTc). Superparamagnetic iron oxide nanoparticles (SPIO) have emerged as a nonradioactive alternative. Used in conjunction with a handheld magnetometer system (Magtrace® and Sentimag®, Endomagnetics Ltd.), SPIO enables SLN detection without the need for nuclear medicine infrastructure. In clinical studies involving breast cancer patients, SPIO has demonstrated non-inferiority to the conventional 99mTc and PB protocol. Given these findings, SPIO is hypothesized to offer equivalent performance in melanoma patients. This study is designed to evaluate the non-inferiority of preoperative magnetic resonance imaging (MRI) using SPIO compared to traditional lymphoscintigraphy and single-photon emission computed tomography/computed tomography with 99mTc for SLN identification in melanoma. Additionally, the study assesses the non-inferiority of intraoperative SLNB using SPIO and the Sentimag® device relative to the current gold standard based on 99mTc. Methods: A prospective, single-arm, non-inferiority study will be conducted at the Department of Surgical Oncology, Zuyderland Medical Center, Sittard, the Netherlands. The study will enroll 140 adult patients diagnosed with stage I-II primary melanoma who are scheduled to undergo wide local excision and SLNB. All participants will undergo lymphatic mapping using both Magtrace® and 99mTc. The MRI protocol, previously evaluated in a pilot study, was demonstrated to be feasible. Implementation of the MRI protocol will proceed if non-inferiority is established within a predefined margin of 5%. Conclusion: Elimination of radiation exposure is beneficial for both patients and healthcare personnel. Moreover, logistic challenges will be eliminated as SPIO can be injected several days before surgery, immediately followed by MRI scanning. Scheduled surgeries will not be jeopardized by preoperative logistics and procedures. It will increase hospital-oriented productivity, patient-friendliness and comfort as surgical delays are avoided.
- 28 November 2025
- Published by S. Karger AG in European Surgical Research
- Vol. 67 (1) , 30-37
Open AccessExploring an Alternative Preoperative Sentinel Lymph Node Mapping Method Using a Magnetic Tracer and Magnetic Resonance Imaging for Melanoma Patients: SCARLETT Study Protocol
Introduction: Sentinel lymph node biopsy (SLNB) plays a critical role in the clinical management of malignant melanoma. The current standard of care involves the preoperative injection of a Technetium-labeled (99mTc) colloidal nanomaterial to facilitate lymphatic mapping. During surgery, patent blue (PB) is administered to enhance visualization of the lymphatic pathways. However, this dual-tracer approach presents notable drawbacks, including patient exposure to ionizing radiation and logistical challenges stemming from the short half-life of (99mTc). Superparamagnetic iron oxide nanoparticles (SPIO) have emerged as a nonradioactive alternative. Used in conjunction with a handheld magnetometer system (Magtrace® and Sentimag®, Endomagnetics Ltd.), SPIO enables SLN detection without the need for nuclear medicine infrastructure. In clinical studies involving breast cancer patients, SPIO has demonstrated non-inferiority to the conventional 99mTc and PB protocol. Given these findings, SPIO is hypothesized to offer equivalent performance in melanoma patients. This study is designed to evaluate the non-inferiority of preoperative magnetic resonance imaging (MRI) using SPIO compared to traditional lymphoscintigraphy and single-photon emission computed tomography/computed tomography with 99mTc for SLN identification in melanoma. Additionally, the study assesses the non-inferiority of intraoperative SLNB using SPIO and the Sentimag® device relative to the current gold standard based on 99mTc. Methods: A prospective, single-arm, non-inferiority study will be conducted at the Department of Surgical Oncology, Zuyderland Medical Center, Sittard, the Netherlands. The study will enroll 140 adult patients diagnosed with stage I-II primary melanoma who are scheduled to undergo wide local excision and SLNB. All participants will undergo lymphatic mapping using both Magtrace® and 99mTc. The MRI protocol, previously evaluated in a pilot study, was demonstrated to be feasible. Implementation of the MRI protocol will proceed if non-inferiority is established within a predefined margin of 5%. Conclusion: Elimination of radiation exposure is beneficial for both patients and healthcare personnel. Moreover, logistic challenges will be eliminated as SPIO can be injected several days before surgery, immediately followed by MRI scanning. Scheduled surgeries will not be jeopardized by preoperative logistics and procedures. It will increase hospital-oriented productivity, patient-friendliness and comfort as surgical delays are avoided.
- Open Access
- 24 August 2024
- Published by Springer Nature in Targeted Oncology
- Vol. 19 (5) , 735-745
lnsights into Adjuvant Systemic Treatment Selection for Patients with Stage III Melanoma: Data from the Dutch Cancer Registry
Background Patient demographics and shared decision making might influence the choice of adjuvant therapy for stage III melanoma. Objective To identify factors for treatment selection of patients diagnosed with stage III melanoma to better understand current treatment decisions and improve further treatment counseling. Patients and Methods Data from 2007 patients diagnosed with stage III melanoma, between December 2018 and 2021, sourced from the Dutch Cancer Registry, were analyzed. Results Among the cohort, 48.7% received no therapy, 45.8% received checkpoint inhibition, and 5.5% received targeted therapy (TT). Patients foregoing therapy were significantly older [67.0 years (range 53.0–77.0) vs. 62.0 year (range 52.0–72.0)], had poorer performance scores (PS), and higher Charlson Comorbidity Index scores compared to those receiving therapy (p < 0.001). Patients undergoing therapy had significantly higher median Breslow thickness (3.3 mm vs. 2.2 mm) and higher prevalence of ulceration (49.9% vs. 38.1%). Those with connective tissue disease and/or congestive heart disease were more likely to receive TT [odds ration (OR) 8.1; 95% confidence interval (CI) 1.7–37.6 and OR 9.3; 95% CI 1.2–72.2, respectively]. Median treatment time among strata for disease recurrence was 4.26 months (3.69–4.82) for immunotherapy and 3.1 months (0.85–5.36) for TT (p = 0.298). Patients who developed recurrent disease were equal across treatment types (p = 0.656). The number of patients with grade 3 complications was different for each treatment type [immunotherapy: 17.8% vs. TT: 37.3% (p < 0.001)]. Conclusions Age, PS, and Breslow thickness seem to influence adjuvant treatment decisions. Clinicians’ preference for immunotherapy might play a role in counseling BRAF-positive patients for adjuvant therapy, this however, cannot be confirmed in this dataset. Overall, only a small proportion of patients completed adjuvant treatment.
- 24 August 2024
- Published by Springer Nature in Targeted Oncology
- Vol. 19 (5) , 735-745
Open Accesslnsights into Adjuvant Systemic Treatment Selection for Patients with Stage III Melanoma: Data from the Dutch Cancer Registry
Background Patient demographics and shared decision making might influence the choice of adjuvant therapy for stage III melanoma. Objective To identify factors for treatment selection of patients diagnosed with stage III melanoma to better understand current treatment decisions and improve further treatment counseling. Patients and Methods Data from 2007 patients diagnosed with stage III melanoma, between December 2018 and 2021, sourced from the Dutch Cancer Registry, were analyzed. Results Among the cohort, 48.7% received no therapy, 45.8% received checkpoint inhibition, and 5.5% received targeted therapy (TT). Patients foregoing therapy were significantly older [67.0 years (range 53.0–77.0) vs. 62.0 year (range 52.0–72.0)], had poorer performance scores (PS), and higher Charlson Comorbidity Index scores compared to those receiving therapy (p < 0.001). Patients undergoing therapy had significantly higher median Breslow thickness (3.3 mm vs. 2.2 mm) and higher prevalence of ulceration (49.9% vs. 38.1%). Those with connective tissue disease and/or congestive heart disease were more likely to receive TT [odds ration (OR) 8.1; 95% confidence interval (CI) 1.7–37.6 and OR 9.3; 95% CI 1.2–72.2, respectively]. Median treatment time among strata for disease recurrence was 4.26 months (3.69–4.82) for immunotherapy and 3.1 months (0.85–5.36) for TT (p = 0.298). Patients who developed recurrent disease were equal across treatment types (p = 0.656). The number of patients with grade 3 complications was different for each treatment type [immunotherapy: 17.8% vs. TT: 37.3% (p < 0.001)]. Conclusions Age, PS, and Breslow thickness seem to influence adjuvant treatment decisions. Clinicians’ preference for immunotherapy might play a role in counseling BRAF-positive patients for adjuvant therapy, this however, cannot be confirmed in this dataset. Overall, only a small proportion of patients completed adjuvant treatment.
- 4 January 2024
- Published by Wiley in Journal of Surgical Oncology
- Vol. 129 (5) , 975-980
Drain‐free mastectomy and flap fixation: The interim analysis of a randomized controlled noninferiority trial
Introduction: Flap fixation after mastectomy has proven to be one of the most promising solutions to reduce seroma formation. Drain placement remains standard practice in many clinics, even though this may be redundant after flap fixation.Methods: This is a prospective randomized controlled trial comparing mastectomy and wound closure using flap fixation with or without drain placement. The primary outcome measure was clinically significant seroma (CSS) incidence. The aim of this interim analysis was to assess the assumptions for the sample size calculation and to provide preliminary results.Results: Between July 2020 and January 2023, 112 patients were included. CSS incidence was 9.1% in the drain group and 21% in the no‐drain group. In total, 10 patients were lost to follow‐up. These numbers are similar to the ones used for the sample size calculation. In the drain group, three patients required interventions for wound complications compared to nine in the no‐drain group (odds ratio: 3.612 [95% confidence interval: 0.898−14.537]).Conclusion: The sample size calculation seems to be correct and no protocol amendments are necessary. Current preliminary results show no significant differences in CSS incidence. Complete results should be awaited to draw a well‐powered conclusion regarding drain policy after mastectomy.
- 4 January 2024
- Published by Wiley in Journal of Surgical Oncology
- Vol. 129 (5) , 975-980
Drain‐free mastectomy and flap fixation: The interim analysis of a randomized controlled noninferiority trial
Introduction: Flap fixation after mastectomy has proven to be one of the most promising solutions to reduce seroma formation. Drain placement remains standard practice in many clinics, even though this may be redundant after flap fixation.Methods: This is a prospective randomized controlled trial comparing mastectomy and wound closure using flap fixation with or without drain placement. The primary outcome measure was clinically significant seroma (CSS) incidence. The aim of this interim analysis was to assess the assumptions for the sample size calculation and to provide preliminary results.Results: Between July 2020 and January 2023, 112 patients were included. CSS incidence was 9.1% in the drain group and 21% in the no‐drain group. In total, 10 patients were lost to follow‐up. These numbers are similar to the ones used for the sample size calculation. In the drain group, three patients required interventions for wound complications compared to nine in the no‐drain group (odds ratio: 3.612 [95% confidence interval: 0.898−14.537]).Conclusion: The sample size calculation seems to be correct and no protocol amendments are necessary. Current preliminary results show no significant differences in CSS incidence. Complete results should be awaited to draw a well‐powered conclusion regarding drain policy after mastectomy.
- 4 January 2023
- Published by Wiley in Journal of Surgical Oncology
- Vol. 127 (5) , 776-781
An adapted protocol for magnetic localisation of nonpalpable breast cancer lesions and sentinel lymph nodes using a magnetic seed and superparamagnetic iron oxide tracer
Background: Localisation techniques for nonpalpable breast cancer lesions and sentinel lymph node biopsy (SLNB) are associated with several drawbacks. A complete magnetic technique using magnetic seeds and superparamagnetic iron oxide tracer could be an interesting alternative. This study describes a clear protocol and the results of a combined magnetic approach.Methods: From August 2021 to February 2022 40 patients undergoing breast conserving surgery with SLNB were eligible for inclusion. Localisation was performed under ultrasound or stereotactic guidance, 1 week before surgery. Subsequently, 1 ml of tracer was injected at least 4 cm away from the tumour. Technetium‐99m (99mTc) was injected 1 day before surgery as control procedure. Outcomes were SLNB time, a number of nodes detected with magnetic tracer including comparison with 99mTc, a success rate of malignant lesion detection and pathological margin assessment.Results: In total, 40 procedures were performed on 39 patients. A median of one node was retrieved. Sentinel nodes were retrieved using MagTrace® with a 92.5% detection rate compared to 99mTc. Wide local excision under magnetic guidance was successful in 35 cases.Conclusions: This paper describes a combined magnetic approach for breast‐conserving surgery and SLNB. An adapted protocol is described and could be used for implementation.
- 4 January 2023
- Published by Wiley in Journal of Surgical Oncology
- Vol. 127 (5) , 776-781
An adapted protocol for magnetic localisation of nonpalpable breast cancer lesions and sentinel lymph nodes using a magnetic seed and superparamagnetic iron oxide tracer
Background: Localisation techniques for nonpalpable breast cancer lesions and sentinel lymph node biopsy (SLNB) are associated with several drawbacks. A complete magnetic technique using magnetic seeds and superparamagnetic iron oxide tracer could be an interesting alternative. This study describes a clear protocol and the results of a combined magnetic approach.Methods: From August 2021 to February 2022 40 patients undergoing breast conserving surgery with SLNB were eligible for inclusion. Localisation was performed under ultrasound or stereotactic guidance, 1 week before surgery. Subsequently, 1 ml of tracer was injected at least 4 cm away from the tumour. Technetium‐99m (99mTc) was injected 1 day before surgery as control procedure. Outcomes were SLNB time, a number of nodes detected with magnetic tracer including comparison with 99mTc, a success rate of malignant lesion detection and pathological margin assessment.Results: In total, 40 procedures were performed on 39 patients. A median of one node was retrieved. Sentinel nodes were retrieved using MagTrace® with a 92.5% detection rate compared to 99mTc. Wide local excision under magnetic guidance was successful in 35 cases.Conclusions: This paper describes a combined magnetic approach for breast‐conserving surgery and SLNB. An adapted protocol is described and could be used for implementation.
- Open Access
- 14 October 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-7
Sentinel lymph node mapping with superparamagnetic iron oxide for melanoma: a pilot study in healthy participants to establish an optimal MRI workflow protocol
Background: Current pre-operative Sentinel Lymph Node (SLN) mapping using dual tracing is associated with drawbacks (radiation exposure, logistic challenges). Superparamagnetic iron oxide (SPIO) is a non-inferior alternative for SLN mapping in breast cancer patients. Limited research has been performed on SPIO use and pre-operative MRI in melanoma patients to identify SLNs. Methods: Healthy participants underwent MRI-scanning pre- and post SPIO-injection during 20 min. Workflow protocols varied in dosage, massage duration, route of administration and injection sites. The first lymph node showing a susceptibility artefact caused by SPIO accumulation was considered as SLN. Results: Artefacts were identified in 5/6 participants. Two participants received a 0.5 ml subcutaneous injection and 30-s massage, of which one showed an artefact after one hour. Four participants received a 1.0 ml intracutaneous injection and two-minute massage, leading to artefacts in all participants. All SLNs were observed within five minutes, except after lower limb injection (30 min). Conclusion: SPIO and pre-operative MRI-scanning seems to be a promising alternative for SLN visualization in melanoma patients. An intracutaneous injection of 1.0 ml SPIO tracer, followed by a two-minute massage seems to be the most effective technique, simplifying the pre-operative pathway. Result will be used in a larger prospective study with melanoma patients. Trial registration: ClinicalTrials.gov (NCT05054062) – September 9, 2021.
- 14 October 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-7
Open AccessSentinel lymph node mapping with superparamagnetic iron oxide for melanoma: a pilot study in healthy participants to establish an optimal MRI workflow protocol
Background: Current pre-operative Sentinel Lymph Node (SLN) mapping using dual tracing is associated with drawbacks (radiation exposure, logistic challenges). Superparamagnetic iron oxide (SPIO) is a non-inferior alternative for SLN mapping in breast cancer patients. Limited research has been performed on SPIO use and pre-operative MRI in melanoma patients to identify SLNs. Methods: Healthy participants underwent MRI-scanning pre- and post SPIO-injection during 20 min. Workflow protocols varied in dosage, massage duration, route of administration and injection sites. The first lymph node showing a susceptibility artefact caused by SPIO accumulation was considered as SLN. Results: Artefacts were identified in 5/6 participants. Two participants received a 0.5 ml subcutaneous injection and 30-s massage, of which one showed an artefact after one hour. Four participants received a 1.0 ml intracutaneous injection and two-minute massage, leading to artefacts in all participants. All SLNs were observed within five minutes, except after lower limb injection (30 min). Conclusion: SPIO and pre-operative MRI-scanning seems to be a promising alternative for SLN visualization in melanoma patients. An intracutaneous injection of 1.0 ml SPIO tracer, followed by a two-minute massage seems to be the most effective technique, simplifying the pre-operative pathway. Result will be used in a larger prospective study with melanoma patients. Trial registration: ClinicalTrials.gov (NCT05054062) – September 9, 2021.
- 29 September 2022
- Published by Wiley in Journal of Surgical Oncology
- Vol. 127 (1) , 28-33
Technical aspects of flap fixation after mastectomy for breast cancer: Guidelines for improving seroma‐related outcome
Objectives: Previous studies have identified the added value of flap fixation in reducing seroma formation and its sequelae after mastectomy. The seroma reduction after mastectomy (SAM)‐trial proved that sutures were superior to tissue glue. In this article, we will elaborate on the results of the SAM‐trial to provide a clear surgical guideline.Methods: All patients in the suture flap fixation cohort from the SAM‐trial were analyzed if details regarding flap fixation were available. The most optimal number of sutures was determined using a receiving operator characteristics curve. The incidence of seroma formation between patients receiving the most optimal number of sutures and patients receiving fewer sutures was compared.Results: The most optimal number of sutures proved to be 15. Patients with ≥15 sutures had a lower incidence of seroma formation at every time frame during follow‐up. There was a significant difference at 6 weeks (odds ratio [OR]: 3.05, 95% confidence interval [CI]: 1.09–8.56), 3 months (OR: 4.62, 95% CI: 1.34–12.92), and 1 year postoperatively (OR: 20.48, 95% CI: 2.18–192.22). Ten days and 6 months postoperatively did not differ significantly.Conclusions: Flap fixation in general, but also the surgical technique influences the incidence of seroma formation after mastectomy. Results suggest a minimum of 15 sutures, spaced approximately 3.7 cm apart.
- 29 September 2022
- Published by Wiley in Journal of Surgical Oncology
- Vol. 127 (1) , 28-33
Technical aspects of flap fixation after mastectomy for breast cancer: Guidelines for improving seroma‐related outcome
Objectives: Previous studies have identified the added value of flap fixation in reducing seroma formation and its sequelae after mastectomy. The seroma reduction after mastectomy (SAM)‐trial proved that sutures were superior to tissue glue. In this article, we will elaborate on the results of the SAM‐trial to provide a clear surgical guideline.Methods: All patients in the suture flap fixation cohort from the SAM‐trial were analyzed if details regarding flap fixation were available. The most optimal number of sutures was determined using a receiving operator characteristics curve. The incidence of seroma formation between patients receiving the most optimal number of sutures and patients receiving fewer sutures was compared.Results: The most optimal number of sutures proved to be 15. Patients with ≥15 sutures had a lower incidence of seroma formation at every time frame during follow‐up. There was a significant difference at 6 weeks (odds ratio [OR]: 3.05, 95% confidence interval [CI]: 1.09–8.56), 3 months (OR: 4.62, 95% CI: 1.34–12.92), and 1 year postoperatively (OR: 20.48, 95% CI: 2.18–192.22). Ten days and 6 months postoperatively did not differ significantly.Conclusions: Flap fixation in general, but also the surgical technique influences the incidence of seroma formation after mastectomy. Results suggest a minimum of 15 sutures, spaced approximately 3.7 cm apart.